Tag Archives: NASDAQ:CELG

Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&A
January 23, 2018

Yesterday Celgene finalized its acquisition of Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. With only a few hundred patients ever treated with their therapies, $20B represents a lot of promise in

Leave a comment